The field of immunotherapy is attracting billions of dollars in investment following the recent approval of Kymriah (Novartis, $475,000) and Yescarta (Kite Pharma/Gilead, $373,000) for B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma patients. This ability to rewire our own immune system to fight cancer has certainly created huge expectations, evident by 240 on-going clinical trials in the field.
In this event, we will have the opportunity to hear from the pioneers doing the most innovative work within the field. We will have a closer look at development, translation and commercialising of immunotherapy treatment as well as focusing on the current challenges scientists facing to reach their gene therapy products to the market.
After the talks we will open the floor to our panel discussion and you will have the opportunity to put your questions to all of our speakers.
Finally the event will be followed by networking reception with wine and snacks.